Myriad Genetics
MYGN
267 hedge funds and large institutions have $2.62B invested in Myriad Genetics in 2013 Q3 according to their latest regulatory filings, with 45 funds opening new positions, 125 increasing their positions, 73 reducing their positions, and 38 closing their positions.
71% more repeat investments, than reductions
Existing positions increased: 125 | Existing positions reduced: 73
22% more capital invested
Capital invested by funds: $2.14B → $2.62B (+$480M)
18% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 38
2% more funds holding
Funds holding: 261 → 267 (+6)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
39% less call options, than puts
Call options by funds: $58.2M | Put options by funds: $95.6M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$104M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
+$86.2M |
| 3 |
MCM
Munder Capital Management
Birmingham,
Michigan
|
+$86M |
| 4 |
MNA
Manning & Napier Advisors
Fairport,
New York
|
+$45.5M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$31.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
-$26.9M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$16.1M |
| 3 |
William Blair & Company
Chicago,
Illinois
|
-$14.5M |
| 4 |
JCI
Jet Capital Investors
New York
|
-$13.6M |
| 5 |
PCMI
Paradigm Capital Management Inc
Albany,
New York
|
-$13.5M |
MYGN Hedge Fund Activity: Q3 2013 in Review
267 of the 3,085 institutional investors tracked by Wall St. Rank reported a position in Myriad Genetics (MYGN) for Q3 2013, worth a combined $2.62B — up 22% from $2.14B a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new MYGN positions and 38 closed out — a net gain of 7 holders — while 125 added to existing stakes and 73 trimmed.
The largest buyer was Baillie Gifford & Co, opening a new position worth an estimated $104M. The largest seller was D.E. Shaw & Co, cutting an estimated $26.9M.
- 267 institutional investors held Myriad Genetics (MYGN) as of Q3 2013, up from 261 in Q2 2013.
- Funds reported $2.62B of Myriad Genetics stock for Q3 2013, up 22% quarter-over-quarter.
- 45 funds opened new Myriad Genetics positions in Q3 2013 and 38 closed out, a net change of +7 holders.
- The largest Myriad Genetics buyer in Q3 2013 was Baillie Gifford & Co, an estimated $104M added.
- The largest Myriad Genetics seller in Q3 2013 was D.E. Shaw & Co, an estimated $26.9M sold.
Based on aggregated 13F filings for Q3 2013.